Related Experiment Video
Updated: Aug 11, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Ear involvement in Wegener's granulomatosis
1ENT-Clinic, University of Tübingen, FR Germany.
Clinical Otolaryngology and Allied Sciences
|October 1, 1989
Summary
Wegener's granulomatosis often initially affects the ear and nose, causing hearing loss. Immunosuppressive therapy shows promise for managing these audiological and serological manifestations.
Area of Science:
- Otolaryngology
- Rheumatology
- Immunology
Background:
- Wegener's granulomatosis is a rare autoimmune disease.
- Early symptoms frequently involve the ear and nose.
- Understanding its otological impact is crucial for timely diagnosis and management.
Purpose of the Study:
- To investigate the audiological and serological findings in patients with Wegener's granulomatosis.
- To assess the relationship between Wegener's granulomatosis and inner ear disorders.
- To evaluate the efficacy of immunosuppressive therapy.
Main Methods:
- Audiological assessments were performed on affected patients.
- Serological tests were conducted to detect specific antibodies.
- Clinical data on disease progression and treatment response were analyzed.
Main Results:
- 16 of 19 patients presented with early ear and nose manifestations.
- Middle ear involvement was observed in 16 of 26 ears.
- Sensorineural hearing loss was prevalent, affecting 21 of 26 ears, with some cases leading to deafness.
- Antibodies against sarcolemma were found in patients with sensorineural hearing loss.
Conclusions:
- Wegener's granulomatosis frequently manifests with otological symptoms, including hearing loss.
- The presence of specific antibodies suggests an autoimmune basis for the inner ear dysfunction.
- Immunosuppressive therapy appears effective in managing the disease course, similar to other immunologically mediated inner ear conditions.
